Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Beyond antipsychotics: pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia.
Swerdlow NR.
Neuropsychopharmacology. 2012 Jan;37(1):310-1. doi: 10.1038/npp.2011.195. No abstract available.
Related citations
Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions.
Feifel D.
Neuropsychopharmacology. 2012 Jan;37(1):304-5. doi: 10.1038/npp.2011.184. No abstract available.
Alpha7 nicotinic acetylcholine receptors modulate motivation to self-administer nicotine: implications for smoking and schizophrenia.
Brunzell DH, McIntosh JM.
Neuropsychopharmacology. 2012 Apr;37(5):1134-43. doi: 10.1038/npp.2011.299. Epub 2011 Dec 14.
Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator.
Gastambide F, Cotel MC, Gilmour G, O'Neill MJ, Robbins TW, Tricklebank MD.
Neuropsychopharmacology. 2012 Mar;37(4):1057-66. doi: 10.1038/npp.2011.298. Epub 2011 Nov 30.
Pharmacological activation of group-II metabotropic glutamate receptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice.
Matrisciano F, Tueting P, Maccari S, Nicoletti F, Guidotti A.
Neuropsychopharmacology. 2012 Mar;37(4):929-38. doi: 10.1038/npp.2011.274. Epub 2011 Nov 16.
Abnormal activity of the MAPK- and cAMP-associated signaling pathways in frontal cortical areas in postmortem brain in schizophrenia.
Funk AJ, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH.
Neuropsychopharmacology. 2012 Mar;37(4):896-905. doi: 10.1038/npp.2011.267. Epub 2011 Nov 2.
Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: a randomized double-blind placebo-controlled trial.
Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, Lee SW, Kong BG, Kang JW, Oh MK, Kim SD, McMahon RP, Kelly DL.
Neuropsychopharmacology. 2012 Feb;37(3):660-8. doi: 10.1038/npp.2011.238. Epub 2011 Nov 2.
Growth arrest and DNA-damage-inducible, beta (GADD45b)-mediated DNA demethylation in major psychosis.
Gavin DP, Sharma RP, Chase KA, Matrisciano F, Dong E, Guidotti A.
Neuropsychopharmacology. 2012 Jan;37(2):531-42. doi: 10.1038/npp.2011.221. Epub 2011 Nov 2.
Reelin, a marker of stress resilience in depression and psychosis.
Fatemi SH.
Neuropsychopharmacology. 2011 Nov;36(12):2371-2. doi: 10.1038/npp.2011.169. No abstract available.
The effects of CACNA1C gene polymorphism on spatial working memory in both healthy controls and patients with schizophrenia or bipolar disorder.
Zhang Q, Shen Q, Xu Z, Chen M, Cheng L, Zhai J, Gu H, Bao X, Chen X, Wang K, Deng X, Ji F, Liu C, Li J, Dong Q, Chen C.
Neuropsychopharmacology. 2012 Feb;37(3):677-84. doi: 10.1038/npp.2011.242. Epub 2011 Oct 19.
Error occurred: cannot get document summary
Endogenic and iatrogenic diabetes mellitus in drug-naïve schizophrenia: the role of olanzapine and its place in the psychopharmacological treatment algorithm.
Cohen D, De Hert M.
Neuropsychopharmacology. 2011 Oct;36(11):2368-9. doi: 10.1038/npp.2011.94. No abstract available.
From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.
Moghaddam B, Javitt D.
Neuropsychopharmacology. 2012 Jan;37(1):4-15. doi: 10.1038/npp.2011.181. Epub 2011 Sep 28.
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.
Jones CK, Byun N, Bubser M.
Neuropsychopharmacology. 2012 Jan;37(1):16-42. doi: 10.1038/npp.2011.199. Epub 2011 Sep 28.
Investigation of anatomical thalamo-cortical connectivity and FMRI activation in schizophrenia.
Marenco S, Stein JL, Savostyanova AA, Sambataro F, Tan HY, Goldman AL, Verchinski BA, Barnett AS, Dickinson D, Apud JA, Callicott JH, Meyer-Lindenberg A, Weinberger DR.
Neuropsychopharmacology. 2012 Jan;37(2):499-507. doi: 10.1038/npp.2011.215. Epub 2011 Sep 28.
Transient inactivation of the neonatal ventral hippocampus permanently disrupts the mesolimbic regulation of prefrontal cholinergic transmission: implications for schizophrenia.
Brooks JM, Sarter M, Bruno JP.
Neuropsychopharmacology. 2011 Nov;36(12):2477-87. doi: 10.1038/npp.2011.136. Epub 2011 Aug 3.
Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder.
Teixeira CM, Martín ED, Sahún I, Masachs N, Pujadas L, Corvelo A, Bosch C, Rossi D, Martinez A, Maldonado R, Dierssen M, Soriano E.
Neuropsychopharmacology. 2011 Nov;36(12):2395-405. doi: 10.1038/npp.2011.153. Epub 2011 Aug 3.
Is there evidence for neurotoxicity in the prodromal and early stages of schizophrenia?
Lahti AC, Reid MA.
Neuropsychopharmacology. 2011 Aug;36(9):1779-80. doi: 10.1038/npp.2011.83. No abstract available.
Selective pyramidal cell reduction of GABA(A) receptor α1 subunit messenger RNA expression in schizophrenia.
Glausier JR, Lewis DA.
Neuropsychopharmacology. 2011 Sep;36(10):2103-10. doi: 10.1038/npp.2011.102. Epub 2011 Jun 15.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on